Natural Cycles, a women’s health company known for developing the world’s first birth control app, has announced the successful closure of its $55 million Series C financing round. The round was led by Lauxera Capital Partners, with additional participation from Point72 Private Investments and a revolving debt facility provided by J.P. Morgan.
Natural Cycles, co-founded in 2013 by Dr. Elina Berglund Scherwitzl and Dr. Raoul Scherwitzl, has made remarkable strides in digital contraceptive solutions, boasting over three million users worldwide. The company’s app is cleared by regulatory authorities in the United States (FDA), Europe (TÜV SÜD), Canada (Health Canada), Australia (TGA), Singapore (HSA), and South Korea (MFDS) as a digital birth control method.
The new funds will be directed towards accelerating the company’s commercial efforts, developing new products, and automating healthcare reimbursement processes. Dr. Raoul Scherwitzl, co-founder and CEO of Natural Cycles, shared: “We’ve experienced profitable growth over the last few years as women actively seek more birth control options and we’re excited to welcome the next phase of Natural Cycles journey together with Lauxera Capital Partners and Point72 Private Investments. We look forward to leveraging their expertise to fulfill Natural Cycles’ mission of making hormone-free birth control more accessible and combining technology and science to fill the gaps in underserved areas of women’s health.”
Scherwitzl also told Axios that Natural Cycles “sought a Series C to bring in growth equity investors with IPO experience”, which points to a possible exit scenario, and that the new funds put the company in “a strong position to make acquisitions if there’s technology we like that complements our roadmap.”
Natural Cycles has recently expanded its offerings with the launch of NC° Postpartum, a new feature within the app designed to support new mothers in their physical and mental recovery after childbirth. This addition complements the app’s existing modes: NC° Birth Control, NC° Plan Pregnancy, and NC° Follow Pregnancy, thereby providing comprehensive support throughout various stages of the fertility journey.
Samuel Levy, founding partner of Lauxera Capital Partners, commented: “Our mission at Lauxera is to partner with ambitious entrepreneurs transforming the future of medicine with unique technology. The visionary Natural Cycles team has built an exceptional company delivering profitable growth supported by unique clinical and regulatory business moats. We are delighted to partner with Elina, Raoul and their team to offer women an alternative to traditional approaches without the side effects and compromises.” As part of the investment, Levy will join Natural Cycles’ Board of Directors.
In addition to Lauxera Capital Partners and Point72 Private Investments, Natural Cycles’ investor base includes EQT Ventures, Samsung Ventures, Heartcore Capital, Headline, and Bonnier Ventures.
